New NK cell platform extends RMTG’s cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia.

MIAMI, FL / ACCESS Newswire / August 24, 2026 / Regenerative Medical Technology Group, Inc. (the “Company” or “RMTG”) (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, announces the launch, through its Cellgenic division, of a Natural Killer (NK) cell product line for permitted markets outside the United States, with an initial commercial focus on Latin America and Southeast Asia.

NK cells are a class of cytotoxic lymphocytes with a growing body of research interest across immunology and cellular-science applications. Cellgenic’s new product line broadens RMTG’s cellular-technology offering to physicians and clinics operating under the regulatory frameworks of its target markets, without making therapeutic claims that would require additional regulatory support.

The Company said international demand for advanced cellular and immunology-related Technology has continued to grow, and that the NK cell launch reflects Cellgenic’s broader strategy of expanding its product portfolio to meet physician and customer demand in permitted markets.

Operational and Strategic Update

David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc., commented: “Natural killer cell technology represents one of the more active areas of interest in cellular science today. Adding an NK cell product line lets Cellgenic meet physician demand we are already seeing internationally, and it is a natural extension of the cellular-technology platform we have built.”

Product-line launches are one of the most direct ways RMTG converts its research, sourcing, and manufacturing capability into near-term commercial opportunity without the capital intensity of new facilities – an efficient, repeatable growth motion the Company intends to continue across its permitted international markets.

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTCID:RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network. The Company operates across more than 30 countries. Additional information about the Company’s business, operations, and risks is available in its filings with the Securities and Exchange Commission.

About Cellgenic

Cellgenic is the biologics and product-commercialization division of Global Stem Cells Group, developing and distributing advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” “may,” “will,” “continue,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and reflect management’s current belief only.

Forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied, including, without limitation: the Company’s ability to continue as a going concern; its liquidity position and need for additional capital; its substantial debt obligations and the risk of acceleration of that indebtedness; its history of operating losses; regulatory developments in the United States, Argentina, and the other jurisdictions in which the Company or its subsidiaries operate; market acceptance, operational execution, and competitive conditions; currency and general economic factors; and the Company’s ability to maintain compliance with applicable laws and the requirements of the OTC market. These and other risks are described more fully under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Information on or accessible through the Company’s website, including RMTG.com, is not incorporated by reference into, and does not form a part of, this press release or the Company’s filings with the Securities and Exchange Commission, which remain the authoritative source of information about the Company. This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

###

Contact:
Investor Relations
Regenerative Medical Technology Group, Inc.
ir@rmtg.com | (800) 956-3935
RMTG.com

SOURCE: Regenerative Medical Technology Group

View the original press release on ACCESS Newswire

Media gallery

About The Author
Regenerative Medical Technology Group